Table 3.
Response rates
| Patients, n (%) | ||
|---|---|---|
| Exemestane (n = 132) | Anastrozole (n = 128) | |
| Complete response | 2 (1.5) | 3 (2.3) |
| Partial response | 56 (42.4) | 47 (36.7) |
| Stable disease | 55 (41.7) | 70 (54.7) |
| Stable disease ≥24 weeks | 41 (31.1) | 49 (38.3) |
| Stable disease <24 weeks | 14 (10.6) | 21 (16.4) |
| Progressive disease | 16 (12.1) | 8 (6.3) |
| Early deatha | 1 (<1.0) | 0 |
| Indeterminate response | 2 (1.5) | 0 |
| Overall response rate (CR + PR) [95 % CI] | 58 (43.9) [35.3, 52.8] | 50 (39.1) [30.6, 48.1] |
| Clinical benefit response rateb [95 % CI] | 99 (75.0) [66.7, 82.1] | 99 (77.3) [69.1, 84.3] |
Adapted with permission from Masuda et al. [24]
CI confidence interval, CR complete response, PR partial response
Based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 [23]
aCause of early death in 1 patient was lung metastasis
bClinical benefit response rate = (CR + PR + stable disease > 24 weeks)/number of patients × 100